Table 3.

Steady-State Pharmacokinetic Parameters of Risperidone Plus 9-hydroxyrisperidone with 50 mg Once-Monthly or 25 mg Biweekly

	50 mg Once Monthly*		25 mg Biweekly [2]
Parameter	n	Mean ± SD	n	Mean ± SD
Cmin,ss, ng/mL	18	6.21 ± 3.1	21	11.3 ± 4.5
Cmax,ss, ng/mL	18	40.4 ± 15.3	21	22.7 ± 9.2
tmax,ss, h	18	240.2 ± 217.2	21	NA
AUCτ, ng·h/mL	17	12,027 ± 4241	21	5303
Cavg,ss, ng/mL	17	17.5 ± 6.1	21	15.8
FI, %	17	199 ± 55.8	21	69 ± 44
Cmax/Cmin ratio	18	7.4 ± 2.8	21	2.4 ± 1.8

NA indicates not available.

*Samples acquired between weeks 24 and 28.

AUCτ: the dosing interval (τ) is 4 weeks for the present study and 2 weeks for Eerdekens M, et al.